详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Automated assessment of CD8+ T-lymphocytes and stroma fractions complement conventional staging of colorectal cancer.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [a]Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China [b]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [c]Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom [d]Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway [e]Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom [f]NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom [g]Department of Informatics, University of Oslo, Oslo, Norway [h]Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

出处：

DOI：

摘要：

Tumor development is critically dependent on the supporting stroma consisting of inflammatory cells and fibroblasts. This study intended to improve prognostic prediction for early colorectal cancer (CRC) by combined estimation of T-lymphocyte and stroma fractions with conventional markers.In total 509 and 1041 stage II/ΙΙΙ CRC from the VICTOR and QUASAR 2 trials were included as a training set and a validation set, respectively. Intratumoral CD8+ T-lymphocytes and stroma were identified and quantified by machine-based learning on digital sections. The primary endpoint was to evaluate the prognostic value of the combined marker for time to recurrence (TTR).For low-risk patients (n = 598; stage Ⅱ, and stage ΙΙΙ pT1-3 pN1 with neither lymphatic (L-) nor vascular (V-) invasion), low stroma fraction (n = 511) identified a good prognostic subgroup with 5-year TTR of 86% (95% CI 83-89), versus the high stroma subgroup TTR of 78% (HR = 1.75, 95% CI 1.05-2.92; P = 0.029). For high-risk patients (n = 394; stage ΙΙΙ pT3 pN1 L+/V+, pT4, or pN2), combined low CD8+ and high stroma fraction identified a poor prognostic subgroup (n = 34) with 5-year TTR of 29% (95% CI 17-50), versus the high CD8+ fraction and low stroma fraction subgroup (n = 138) of 64% (HR = 2.86, 95% CI 1.75-4.69; P < 0.001).Quantification of intratumoral CD8+ T-lymphocyte and stroma fractions can be combined with conventional prognostic markers to improve patient stratification.Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区医学：研究与实验

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区医学：研究与实验

第一作者：

第一作者机构： [a]Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China [b]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China [c]Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

通讯作者：

通讯机构： [a]Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China [c]Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom [d]Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway [g]Department of Informatics, University of Oslo, Oslo, Norway [h]Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]West China Hospital, No.37 Guoxue Alley, Wuhou District, Chengdu 610041, China. [*2]Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway

推荐引用方式(GB/T 7714)：

APA：

MLA：